2021 American Transplant Congress
Cost-Effectiveness Analysis of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…2021 American Transplant Congress
Are Tacrolimus Concentrations Reduced with Direct-acting Antiviral Administration in Transplant Recipients?
Pharmacy, Penn State Health Hershey Medical Center, Hershey, PA
*Purpose: To evaluate the effects of direct-acting antivirals (DAAs) on tacrolimus trough concentrations and clinical outcome and to assess the need for a priori dose…2020 American Transplant Congress
Utilization of Kidneys from Deceased Donors with Positive Hepatitis C Nucleic Acid Amplification Testing (HCV NAT+)
Columbia University, New York, NY
*Purpose: With modern direct-acting antiviral agents, transplantation of kidneys from HCV NAT+ deceased donors for recipients with or without HCV has expanded the kidney supply.…2020 American Transplant Congress
Evaluating the Effect of HCV Status on the KDPI in the Era of DAA Therapy
*Purpose: The association between KDPI and kidney graft outcomes is limited in the era of DAA therapy.*Methods: We analyzed adult renal transplants, at the University…2020 American Transplant Congress
Viral Kinetics of De Novo HCV Infection and Response to Antiviral Therapy in Liver and Kidney Transplant Recipients Receiving HCV-Viremic Donors
*Purpose: There is general agreement that expanded use of organs from HCV-viremic donors is desirable, including in recipients without HCV infection. However, the optimal treatment…2020 American Transplant Congress
Transplanting Livers from Hepatitis C Virus Positive Donors; Is it Worth the Risk?
*Purpose: Before the introduction of Direct-Acting Antivirals (DAAs), only selected organs from Hepatitis C virus (HCV) positive donors were successfully transplanted into HCV positive recipients.…2020 American Transplant Congress
Hepatitis C Antibody Seroconversion in Kidney Transplant Patients from HCV Antibody Positive/NAT Negative Donors Does Not Deteriorate Renal Allograft Outcome
Loma Linda University, Transplant Institute, San Bernadino, CA
*Purpose: Prior studies have shown that almost 50% of kidney transplant patients from hepatitis C Ab+/NAT - donors have seroconverted but its impact on renal…2020 American Transplant Congress
HCV Viremic Kidneys for Uninfected Recipients with DAA Treatment Offers Sustained Virologic Response
Montefiore Medical Center, Bronx, NY
*Purpose: Development of direct acting anti-viral medications (DAA) have offered cure rates for hepatitis C infection (HCV) approaching 100%. This has provided the ability to…2020 American Transplant Congress
Real-World Experiences in the Transplantation of Hepatitis C Positive Kidneys
*Purpose: With advancements of direct-acting antivirals, transplantation of HCV-NAT+ (HCV+) organs to HCV-negative (HCV-) recipients has been used to decrease wait times without apparent sacrifice…2020 American Transplant Congress
Experiences and Challenges Faced by Organ Transplant Recipients with Donor-Derived Hepatitis C Virus Infection
*Purpose: Recently, transplantation of organs from viremic donors with hepatitis C virus (HCV-V) has increased. Currently, there is a lack of standardization of consent forms…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 28
- Next Page »